- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00753766
Multifactorial Pre-operative Intervention in Diabetes Mellitus
Multifactorial Pre-Operative Intervention in Diabetes Mellitus
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Patients with diabetes that require hospitalization are at increased risk for morbidity and mortality, especially when undergoing surgery. There is some evidence that intensive glucose management during hospitalization may improve outcomes. However, no studies have evaluated intensive diabetes treatment before hospitalization.
Preliminary data from patients having vascular surgery show that those with diabetes have longer hospital stays, more frequent wound infections, and are more likely to require a return to the operating room when compared to patients without diabetes. In particular, insulin-treated patients have even greater peri-operative complications than non-insulin treated patients with diabetes. However, these data also suggest that a clinical trial to test the hypothesis that pre-operative intensive management has significant impact on peri-operative complications would require a very large number of participants to have adequate power.
Thus, our objective is to conduct a pilot and feasibility study to determine whether an intervention that involves intensive pre-operative diabetes management can be successfully implemented and to assess whether trends for benefit are observed. The results of this trial will support the conduct of a definitive study that tests the effectiveness of such an intervention in a larger sample of patients.
This is a randomized, parallel group clinical trial in insulin-treated patients with diabetes mellitus who have been scheduled for elective vascular surgery. We will randomize 46 participants diabetes mellitus: insulin-treated with HbA1c 7.5% or treated with oral agents with an elevated HbA1c who are scheduled for vascular surgery and in whom a 6 week pre-operative delay poses no substantial medical risks, as determined by the staff surgeon. We will exclude individuals with markedly elevated HbA1c or blood pressure; those with recently manifest cardiovascular disease, and those unable to attend regularly scheduled follow-up visits during the pre-operative period.
Participants will be randomized to either continue with usual care or participate in a multifactorial intervention conducted over a 6-week period. During the intervention period, participants will meet with a care manager and/or endocrinologist on at least 3 occasions and have telephone follow-up between these visits. They will receive instruction on lifestyle modifications; measure glucose and blood pressure at home (including the use of a continuous glucose monitoring device on 2 occasions), and receive care management to optimize glucose, blood pressure, and lipid lowering, as appropriate.
The primary outcome measure is the percent of screened participants that are eligible and choose participation Secondary end points will include: participant adherence with the study protocol, change from baseline in A1c and fructosamine, occurrence of wound infections in the 30-day peri-operative period, a composite of death from cardiovascular causes, non-fatal myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, nonfatal stroke, or amputation as a result of peripheral ischemia; length of hospital stay; and rate of return to the operating room.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Diagnosis of diabetes mellitus
- A1c 7.5%,
- Scheduled elective vascular surgery that may be safely deferred for 6 weeks
- Surgeon's approval to participate
Exclusion Criteria:
- Hemoglobin A1c >14% (This criterion was included since, once identified, such a patient warrants improved glucose control and can not be ethically entered into a trial where there is a 50% chance of being assigned to usual care)
- Myocardial infarction in prior 6 months
- Cerebrovascular disease in prior 6 months
- Active cancer requiring ongoing treatment
- Severe psychiatric disease limiting ability to comply with protocol
- Unable to attend follow up appointments
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Sin intervención: Cuidado usual
Grupo de control
|
|
Experimental: Multifactorial Intervention
Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Percent of Screened Participants That Are Eligible and Choose Participation
Periodo de tiempo: 6 weeks
|
6 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants With Full Adherence to the Study Protocol (i.e. Attending Study Visits, CGMS Studies)
Periodo de tiempo: 6 weeks
|
6 weeks
|
|
Percentage of Participants Not Completing the Protocol Due to the Need for Urgent Surgery and/or Treatment-related Complications
Periodo de tiempo: 6 weeks
|
6 weeks
|
|
Change in A1c From Baseline to Pre-admission (A1c is the Standard Parameter to Assess Chronic Glucose Control])
Periodo de tiempo: 6 weeks
|
A1c measured at two time points - baseline and 6 weeks later (pre-admission).
This parameter is the difference between those two time points.
|
6 weeks
|
Number of Participants With Occurrence of Wound Infection in the 30 Day Post-operative Period
Periodo de tiempo: 30 days
|
30 days
|
|
Length of Hospital Stay
Periodo de tiempo: 6 weeks
|
6 weeks
|
|
Number of Participants Who Experience a Composite of Death From Cardiovascular Cause, Non-fatal Myocardial Infarction, Coronary Artery Bypass Grafting, Percutaneous Coronary Intervention, Nonfatal Stroke, or Amputation as a Result of Peripheral Ischemia
Periodo de tiempo: 6 weeks
|
6 weeks
|
|
Percentage of Participants Who Need to Return to the Operating Room
Periodo de tiempo: 6 weeks
|
6 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Paul R. Conlin, MD, VA Boston Healthcare System West Roxbury Campus, West Roxbury, MA
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CLIN-004-04F
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes mellitus
-
Meir Medical CenterTerminadoDiabetes mellitus tipo 2 | Diabetes Mellitus, No Insulino Dependiente | Diabetes Mellitus, sobre Tratamiento Hipoglucemiante Oral | Diabetes mellitus tipo adultoIsrael
-
Medical College of WisconsinMedical University of South CarolinaTerminadoDiabetes mellitus | Diabetes mellitus tipo 2 | Diabetes mellitus de inicio en adultos | Diabetes mellitus no insulinodependiente | Diabetes mellitus no insulinodependiente, tipo IIEstados Unidos
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.TerminadoDiabetes Mellitus, Tipo 1 | Diabetes tipo 1 | Diabetes tipo 1 | Diabetes mellitus tipo 1 | Diabetes autoinmune | Diabetes Mellitus, Insulino-Dependiente | Diabetes de inicio juvenil | Diabetes Autoinmune | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | Diabetes Mellitus... y otras condicionesEstados Unidos
-
SanofiTerminadoDiabetes Mellitus Tipo 1-Diabetes Mellitus Tipo 2Hungría, Federación Rusa, Alemania, Polonia, Japón, Estados Unidos, Finlandia
-
Guang NingReclutamientoDiabetes mellitus tipo 2 | Diabetes mellitus tipo 1 | Diabetes monogenética | Diabetes pancreatogénica | Diabetes mellitus inducida por fármacos | Otras formas de diabetes mellitusPorcelana
-
Hoffmann-La RocheRoche DiagnosticsTerminadoDiabetes Mellitus Tipo 2, Diabetes Mellitus Tipo 1Alemania
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Activo, no reclutandoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminadoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminadoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
University of California, San FranciscoJuvenile Diabetes Research FoundationTerminadoDiabetes mellitus tipo 1 | Diabetes Mellitus, Tipo I | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | IDDMEstados Unidos, Australia
Ensayos clínicos sobre Multifactorial Intervention
-
United Arab Emirates UniversityReclutamientoEnfermedad renal diabética | Deficiencia de magnesio | Desequilibrio de potasioEmiratos Árabes Unidos
-
Jordi Gol i Gurina FoundationCarlos III Health InstituteTerminadoDeterioro Cognitivo | Ancianos frágiles | DependenciaEspaña
-
Andalusian Regional Ministry of HealthSpanish Society of Family and Community Medicine; Andalusian Society of Family...Terminado
-
Hospital Costa del SolReclutamientoInfecciones por VIH | Síndrome de FragilidadEspaña
-
Dr. Pere Roura-PochDesconocidoEsquizofrenia | Factor de riesgo cardiovascularEspaña
-
University Hospitals, LeicesterDepartment of Health, United KingdomDesconocidoDiabetes mellitus tipo 2Reino Unido
-
Heart Care FoundationTerminadoInfarto de miocardioSuiza, Italia
-
University of AarhusAarhus University Hospital; Rigshospitalet, Denmark; Glostrup University Hospital... y otros colaboradoresTerminadoLesión cerebral traumática (LCT) | Comportamiento agitadoDinamarca
-
Asan Medical CenterPyeongChang Health Center & County HospitalTerminadoFragilidadCorea, república de
-
Louis Stokes VA Medical CenterTerminadoInsuficiencia renal cronicaEstados Unidos